Magazine
Leading the way
Annelies Missotten, Chief Human Resources Officer and Valeria Cnossen, General Counsel, are the newest executive members of the Galapagos Management Committee. What is their view on leadership?
The future of CAR-T at point-of-care
We believe that real differentiation and access to therapy can come from a disruptive decentralized CAR-T manufacturing model at point-of-care, close to patients, combined with innovative science and expert teams.
Living with RA and UC
Heidi, Mireille and Garry share their experience about living with immunological diseases, rheumatoid arthritis (RA) and ulcerative colitis (UC). Three stories about getting through the day the best way possible.
CAR-T
Chimeric antigen receptor T cells (also known as CAR-T cells) are T cells that have been genetically engineered to produce an artificial T cell receptor for use in immunotherapy
Point-of-care
Drug treatment is provided close to or near the patient
Rheumatoid arthritis (RA)
A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability
Ulcerative colitis (UC)
UC is an IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract)